Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group

BACKGROUND: Erwinia asparaginase is a Food and Drug Administration approved agent for the treatment of acute lymphoblastic leukemia (ALL) for patients who develop hypersensitivity to Escherichia coli derived asparaginases. Erwinia asparaginase is efficacious, but has a short half-life, requiring six...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pediatr Blood Cancer
Main Authors: Rau, Rachel E., Dreyer, ZoAnn, Choi, Mi Rim, Liang, Wei, Skowronski, Roman, Allamneni, Krishna P., Devidas, Meenakshi, Raetz, Elizabeth A., Adamson, Peter C., Blaney, Susan M., Loh, Mignon L, Hunger, Stephen P.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5839116/
https://ncbi.nlm.nih.gov/pubmed/29090524
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.26873
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados